一例罕见的前列腺腺泡腺癌和原发性前列腺尿路上皮癌并发病例：病例报告和文献综述
A rare case of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: case report and literature review.
摘要(中文译文)
腺泡腺癌是前列腺癌最常见的亚型，而原发性前列腺尿路上皮癌在临床上较为罕见。两者同时发生在前列腺内的复合性肿瘤则更为罕见，目前临床报道及诊治经验有限。本文报道1例75岁男性患者，同时患有前列腺腺泡腺癌和原发性前列腺尿路上皮癌。患者因体检发现前列腺特异性抗原（PSA）水平升高2年入院。术前磁共振成像（MRI）显示前列腺左侧外周带结节，随后行根治性前列腺切除术。术后病理诊断示前列腺腺泡腺癌（Gleason评分4+3，pT3b期）及原发性前列腺尿路上皮癌伴微浸润（<0.1 cm）。患者术后6个月接受维迪西妥单抗靶向治疗，术后10个月膀胱黏膜多点活检未见肿瘤组织。截至本报告时，患者已随访15个月，未见肿瘤复发证据。前列腺腺泡腺癌合并原发性前列腺尿路上皮癌的复合性肿瘤在临床上较为罕见。明确诊断需结合影像学检查、组织病理学观察及免疫组化检测进行综合判断。应根据多学科会诊制定个体化治疗方案，并对患者进行长期密切随访以监测肿瘤复发。
Abstract
Acinar adenocarcinoma is the most common subtype of prostate cancer, while primary prostatic urothelial carcinoma is clinically rare. The composite tumor with both occurring simultaneously within the prostate is even rarer, with limited clinical reports and diagnostic and therapeutic experience available to date. This article reports a case of a 75-year-old male with concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma. The patient was admitted to the hospital due to an elevated prostate-specific antigen (PSA) level detected during physical examination for 2 years. Preoperative magnetic resonance imaging (MRI) showed a nodule in the left peripheral zone of the prostate, and radical prostatectomy was performed subsequently. Postoperative pathological diagnosis revealed prostatic acinar adenocarcinoma (Gleason score 4 + 3, pT3b stage) and primary prostatic urothelial carcinoma with microinvasion (<0.1 cm). The patient received disitamab vedotin targeted therapy 6 months after surgery, and multi-point biopsy of the bladder mucosa 10 months after surgery showed no tumor tissue. At the time of this report, the patient had undergone 15 months of follow-up with no evidence of tumor recurrence. The composite tumor of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma is clinically rare. Definitive diagnosis requires comprehensive judgment based on imaging examinations, histopathological observation and immunohistochemical detection. Individualized treatment plans should be formulated based on multidisciplinary consultation, and long-term close follow-up of patients is necessary to monitor tumor recurrence.
如何引用
AMA
Yan Xia, Yamei Deng. A rare case of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: case report and literature review.. Frontiers in medicine. 2026; doi:10.3389/fmed.2026.1830418.
APA
Yan Xia, Yamei Deng (2026). A rare case of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: case report and literature review.. Frontiers in medicine. https://doi.org/10.3389/fmed.2026.1830418
GB/T 7714
Yan Xia, Yamei Deng. A rare case of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: case report and literature review.[J]. Frontiers in medicine, 2026 doi:10.3389/fmed.2026.1830418.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出